Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$22 Mln
P/E Ratio
--
P/B Ratio
1.56
Industry P/E
--
Debt to Equity
0
ROE
-0.91 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-95.31 Mln
EBITDA
$-42.08 Mln
Net Profit
$-40.02 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
| -28.73 | 0.78 | -39.15 | 92.54 | -27.53 | -37.01 | -- |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
| 251.26 | -84.06 | -53.62 | -75.07 | 23.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 1.93 | 5.00 | -- | -97.78 | |
| 0.23 | 43.77 | -- | -- | |
| 0.27 | 5.44 | -- | -1185.51 | |
| 0.57 | 3.49 | -- | -- |
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal... antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel. Address: Building 7, Tel Aviv, Israel, 6158002 Read more
Co-Founder, Chief Scientific Officer, CEO & Executive Director
Dr. Adi Mor George Ph.D.
Co-Founder, Chief Scientific Officer, CEO & Executive Director
Dr. Adi Mor George Ph.D.
Headquarters
Tel Aviv
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Chemomab Therapeutics Ltd DRC (CMMB) stood at $ 33 Mln as on 31-Mar-25
The share price of Chemomab Therapeutics Ltd DRC (CMMB) is $1.29 (NASDAQ) as of 24-Apr-2025 16:00 EDT. Chemomab Therapeutics Ltd DRC (CMMB) has given a return of -27.53% in the last 3 years.
Chemomab Therapeutics Ltd DRC (CMMB) has a market capitalisation of $ 22 Mln as on 22-Apr-2025. As per Value Research classification, it is a company.
The P/B ratio of Chemomab Therapeutics Ltd DRC (CMMB) is 1.56 times as on 22-Apr-2025, a 29% discount to its peers’ median range of 2.20 times.
Since, TTM earnings of Chemomab Therapeutics Ltd DRC (CMMB) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Chemomab Therapeutics Ltd DRC (CMMB) and enter the required number of quantities and click on buy to purchase the shares of Chemomab Therapeutics Ltd DRC (CMMB).
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel. Address: Building 7, Tel Aviv, Israel, 6158002
The CEO & director of Dr. Adi Mor George Ph.D.. is Chemomab Therapeutics Ltd DRC (CMMB), and CFO & Sr. VP is Dr. Adi Mor George Ph.D..
There is no promoter pledging in Chemomab Therapeutics Ltd DRC (CMMB).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
4
|
|
|
1
|
|
|
1
|
|
|
0
|
| Chemomab Therapeutics Ltd DRC (CMMB) | Ratios |
|---|---|
|
Return on equity(%)
|
-87.36
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Chemomab Therapeutics Ltd DRC (CMMB) was $0 Mln.
$0.09
(
